In our study, patients with stage IB-IIIB NSCLC were treated with platinum-based NACT preoperatively, and we examined the expression of immune markers related to the cGAS-STING pathway and the density of tumor-infiltrating lymphocytes in tumor tissues before and after NACT, respectively. This evidence concerns the gene STING1 and non-small cell lung carcinoma.